EU nod for Pfizer’s Besponsa
Pfizer’s antibody drug conjugate Besponsa has become the first to be approved by regulators in Europe to treat some adults with the rare, aggressive cancer acute lymphoblastic leukaemia (ALL).
Read More
Tag: inotuzumab
NICE rejects Pfizer’s ALL drug Besponsa
The National Institute for Health and Care Excellence has today published draft guidance not recommending Pfizer’s Besponsa to treat some patients with leukaemia on the NHS in England and Wales.
Read More
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
